Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
Archana RaiKim A ConnellySubodh VermaC David MazerHwee TeohMing-Yen NgIdan RoifmanAdrian QuanMarina PourafkariLaura Jimenez-JuanVenkat RamananYin GeDjeven P DevaAndrew T YanPublished in: Acta diabetologica (2022)
Keyphrases
- left ventricular
- coronary artery disease
- heart failure
- hypertrophic cardiomyopathy
- aortic stenosis
- acute myocardial infarction
- cardiac resynchronization therapy
- percutaneous coronary intervention
- mitral valve
- left atrial
- cardiovascular events
- coronary artery bypass grafting
- atrial fibrillation
- blood pressure
- cardiovascular disease
- acute coronary syndrome